Navigation Links
ESA map reveals European shipping routes like never before
Date:5/22/2009

A synoptic view of European shipping routes can be seen for the first time thanks to a new map created using seven years of radar data from ESA's Envisat satellite.

Earth observation satellites have been providing ship-detecting services for several years, but this is the first time this amount of data collected over an extended period has been processed to produce an overview of ship traffic patterns.

Dr Vincent Kerbaol and Guillaume Hajduch of France's CLS (a subsidiary of the French space agency, CNES) created the map based on a new ship detection algorithm they developed. Using this algorithm, they processed near-real time products from Envisat's Advanced Synthetic Aperture Radar (ASAR) from 2002 to 2009.

Hajduch calibrated the products they retrieved from the ESA archive and then, because ships appear as bright points in radar images, identified the bright pixels located in marine areas.

Despite the fact that ships are more energy efficient than other forms of commercial transportation, many marine engines operate on extremely dirty fuel that causes large emissions of air pollutants like sulphur dioxide (SO2) and nitrogen dioxide (NO2).

SO2 and NO2 emissions from ships are responsible for acid rain, which is harmful to the environment, and particulate matter, which is harmful to humans. As well as detecting emissions from industry and other commercial means of transportation, NO2 emissions from ships can be measured from space along major shipping routes. To illustrate this, a NO2 map has been placed on top of the shipping route map in the above animation. The routes clearly correspond to the pattern of detected NO2.

Sea surface monitoring of ships is very important for observing marine transportation and can help marine authorities ensure admiralty routes are being observed.

For instance, the Maritime Safety Com
'/>"/>

Contact: Mariangela D'Acunto
mariangela.dacunto@esa.int
39-069-418-0856
European Space Agency
Source:Eurekalert  

Page: 1 2

Related biology news :

1. U of Minnesota research reveals critical role of evolutionary processes in species coexistence
2. Diuscovery in amber reveals ancient biology of termites
3. Study reveals conflict between doctors, midwives over homebirth
4. First neuroimaging study examining motor execution in children with autism reveals new insights
5. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
6. New study reveals the protein that makes phosphate chains in yeast
7. Study reveals potential to amass more carbon in eastern North American forests
8. Tentacles of venom: New study reveals all octopuses are venomous
9. New method for detection of phosphoproteins reveals regulator of melanoma invasion
10. Study reveals potential to amass more carbon in eastern North American forests
11. Model tissue system reveals cellular communication via amino acids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ESA map reveals European shipping routes like never before
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... scientists, including Dr Paul Brotherton from the University of ... farmers into Europe had a major impact on the ... Communications , investigates a major component of the maternal ... H mitochondrial genomes from ancient human remains. This genetic ...
... the University of Pittsburgh School of Medicine shows that ... oxidative stress and gene activation patterns akin to disorders ... were recently reported in the online version of the ... (TBI) has become an important issue in combat casualty ...
... International Liver CongressTM 2013 has demonstrated the, accuracy of ... Non Alcoholic Fatty Liver disease (NAFLD) comprises two ... relatively benign and one group with NASH which may ... the only means of distinguishing the two was to ...
Cached Biology News:
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private ... to local area veterinarians. , The tour and course will be given every Wednesday ... at VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as ...
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, ... diversified life sciences company, today announced that its stockholders ... of common stock of the Company from 1,000,000,000 to ... July 27, 2015 at the Law Offices of Nixon ... the Special Meeting, there were 480,655,929 shares of common ...
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... - Clinical benefit observed in over 60% of evaluable ... Exelixis, Inc.,(Nasdaq: EXEL ) today reported interim data ... therapy for patients with non-small cell,lung cancer (NSCLC). This ... with stage IIIB or IV NSCLC who have adenocarcinoma,histology ...
... Imagine using minuscule structures the size of molecules to ... the same structures to store hydrogen fuel so that ... todays semiconductors with these structures, ushering in the next ... exist yet, but the work of a researcher at ...
... Fla., Sept. 4 ,Zimmer Holdings, Inc. (NYSE: ... orthopaedics,industry, and Tutogen Medical, Inc., a leading manufacturer ... and animal,(xenograft) tissue, today announced the expansion of ... subsidiary of Zimmer Holdings,Inc., into Europe, the Middle ...
Cached Biology Technology:Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 4Two nanostructures are better than one 2Two nanostructures are better than one 3Two nanostructures are better than one 4Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 2Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 3Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 4Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 5
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Medium bottle for hybridization 250 x 35mm...
Request Info...
Biology Products: